Anionic Dinuclear Oxidovanadium(IV) Complexes with Azo Functionalized Tridentate Ligands and μ-Ethoxido Bridge Leading to an Unsymmetric Twisted Arrangement: Synthesis, X-ray Structure, Magnetic Properties, and Cytotoxicity

Synthesis of N-heterocyclic carbene‑selenium complexes modulating apoptosis and autophagy in cancer cells: Probing the interactions with biomolecules and enzymes

Growing cancer resistance is a global threat that calls for development of newer chemotherapeutic analogues especially targeted based therapy to enhance efficacy and selectivity. In this contribution, herein, we report synthesis of selenium incorporated N-heterocyclic carbene (NHC) compounds to explore their potential cytotoxicity against HeLa cells. Test compounds were assured for suitability as drug candidates through physiochemical properties that showed lipophilicity logP 0.85-1.45 for C1-C3 and found stable in biological media (DMEM), whereas, least reactive with N-acetyl cysteine (NAC) and L-glutathione. All the studied compounds showed good cytotoxicity against various cancer strains while compound C1 [3,3-(hexane-1,6-diyl)bis(1-phenethyl-1H-imidazole-2(3H)-selenone)] and C2 [3,3-(hexane-1,6-diyl)bis(1-decyl-1H-imidazole-2(3H)-selenone)] showed promising results with IC50 values of 14.65 ± 0.66 and 8.05 ± 0.35 μg/mL respectively as compared to positive control 21.5 ± 0.05 μg/mL against HeLa cell lines. These compounds showed six-fold higher apoptosis than control with higher accumulation of Ca+ ions intracellularly that alters the expression level of autophagy proteins and increased capase-9 activity. Cell cycle analysis indicated an arrest of cycle in G1 phase of HeLa cells when treated with C1 & C2. Test compounds showed prominent affinity for binding with DNA and inhibiting thioredoxin reductase enzymes in time dependent manners. These findings indicate that Selenium NHC compounds are promising drug candidates to induce cytotoxicity via apoptosis, autophagy and mitochondrial membrane disruptions to manage tumor growth.

Unsymmetrical salen-based oxido VIV: Synthesis, characterization, biomolecular interactions, and anticancer activity

Three stable oxidovanadium(IV) [VIVOL1-3] complexes (1-3) were synthesized through the incorporation of unsymmetrical salen ligands (H2L1-3). All the ligands are synthesized, and their vanadium compounds were thoroughly characterized by CHNS analysis, various spectroscopy methods (IR, UV-Vis, NMR spectroscopy), and HR-ESI-MS. The structures of 1-3 were validated through the single-crystal X-ray analysis. UV-Vis and HR-ESI-MS were used to determine the solution stability of the complexes in the aqueous phase, revealing their stability in aqueous/biological medium. Various spectroscopy techniques were used to study the DNA/BSA binding abilities, and the results indicate that 1-3 shows effective biomolecular interactions. The partition coefficient result indicates that 1-3 are highly hydrophobic and may easily permeate the cells. Finally, the in vitro anticancer properties of 1-3 were determined with two cancerous (HT-29 and A549), and the NIH-3T3 normal cell lines. Among the series, 3 is the most cytotoxic, with IC50 values of 6.2 ± 0.2 and 5.3 ± 0.4 μM against HT-29 and A549 cell lines respectively. Moreover, the apoptotic cell death mechanism of 1-3 was assessed through DAPI, AO/EB, and double staining apoptosis experiments.

RuIII-Morpholine-Derived Thiosemicarbazone-Based Metallodrugs: Lysosome-Targeted Anticancer Agents

The idea of coordinating biologically active ligand systems to metal centers to exploit their synergistic effects has gained momentum. Therefore, in this report, three RuIII complexes 1-3 of morpholine-derived thiosemicarbazone ligands have been prepared and characterized by spectroscopy and HRMS along with the structure of 2 through a single-crystal X-ray diffraction study. The solution stability of 1-3 was tested using conventional techniques such as UV-vis and HRMS. Further, the anticancer activity of 1-3 was tested in HT-29 and HeLa cancer cell lines. To gain insight into their mechanism of action, the cytotoxicity, hydrophobicity, and the interaction of 1-3 with DNA and HSA were evaluated by different conventional methods such as absorption, fluorescence, and circular dichroism studies. Along with favorable biomolecule interaction, 1-3 revealed potent selectivity toward cancer cells, which is a prerequisite for the generation of an anticancer drug. According to cell viability results, 1 has the highest cytotoxicity among all in the group, against both cells, respectively. Additionally, the fluorescence-active ruthenium complexes selectively target lysosomes, which is evaluated by live-cell imaging. 1-3 disrupt the lysosome membrane potential by generating an excessive amount of reactive oxygen species, which results in an apoptotic mode of cell death.

Insights into the Theranostic Activity of Nonoxido VIV: Lysosome-Targeted Anticancer Metallodrugs

Developing new anticancer agents can be useful, with the ability to diagnose and treat cancer worldwide. Previously, we focused on examining the effects of nonoxidovanadium(IV) complexes on insulin mimetic and cytotoxicity activity. In this study, in addition to the cytotoxic activity, we evaluated their bioimaging properties. This study investigates the synthesis of four stable nonoxido VIV complexes [VIV(L1-4)2] (1-4) using aroylhydrazone ligands (H2L1-4) and their full characterization in solid state and the solution phase stability using various physicochemical techniques. The biomolecular (DNA/HSA) interaction of the complexes was evaluated by using conventional methods. The in vitro cytotoxicity of 1-4 was studied against A549 and LN-229 cancer cell lines and found that drug 2 displayed the highest activity among the four. Since 1-4 are fluorescently active, live cell imaging was used to evaluate their cellular localization activity. Complexes specifically target the lysosome and damage lysosome integrity by producing an excessive amount (9.7-fold) of reactive oxygen species (ROS) compared to the control, which may cause cell apoptosis. Overall, this study indicates that 2 has the greatest potential for the development of multifunctional theranostic agents that combine imaging capabilities and anticancer properties of nonoxidovanadium(IV)-based metallodrugs.

Monomeric copper(II) complexes with unsymmetrical salen environment: Synthesis, characterization and study of biological activities

Three new ONNO-donor tetradentate unsymmetrical salen ligands were synthesized by using o-phenyl diamine with substituted salicylaldehydes followed by a two-step reaction methodology. These three ligands by reaction with Cu(OAc)2.4H2O produced three new monomeric Cu(II) complexes, [CuII(L1-3)] (1-3). Elemental analysis, IR, UV-vis, NMR, and HR-ESI-MS techniques were used to analyze and characterize all the synthesized ligands and their corresponding metal complexes. Molecular structures of 1-3 were confirmed by the single-crystal-XRD analysis. Furthermore, the DNA binding ability of these complexes was checked through UV-vis, fluorescence spectroscopy, and also by circular dichroism studies. All the complexes were found to show an intercalation mode of binding with the Kb value in the range of 104-105 M-1. Finally, 1-3 was tested against two malignant (HeLa and A549) and non-cancerous (NIH-3T3) cell lines to check their in vitro antiproliferative activities. Among all, 1 is the most cytotoxic of the series having IC50 values of 5.7 ± 0.9 and 6.0 ± 0.3 μM against HeLa and A549 cell lines, respectively. This result is also consistent with the DNA binding order. Furthermore, the apoptotic mode of cell death of all the complexes was also evaluated by DAPI, AO/EB, and Annexin V-FITC/PI double staining assays.

Hydrolytically Stable TiIV-Hydrazone-Based Metallodrugs: Protein Interaction and Anticancer Potential

In this work, three titanium(IV) [TiIV(L1-3)2] (1-3) complexes have been reported using three different tridentate dibasic ONO donor hydrazone ligands, pyridine-4-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L1), furan-2-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L2), and thiophene-2-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L3) tethered with heterocyclic moieties. Elemental analysis, FT-IR, UV-vis, NMR, HR-ESI-MS, and single-crystal X-ray analysis have been used to characterize H2L1-3 and 1-3. In solid structures of 1-3, two ligand molecules with N2O4 donor sets give distorted octahedral geometries to the metal center. The aqueous stability of 1-3 was investigated and well correlated to their perceived pharmacological results. During the investigation, all three complexes were found to be hydrolytically stable in a 90% DMSO-d6/10% D2O (v/v) medium up to 48 h. Furthermore, the interaction of 1-3 with bovine serum albumin (BSA) was tested using fluorescence and absorption techniques. The complexes showed static quenching with a biomolecular quenching constant of Kq ∼ 1013 proposing a high affinity of complexes for BSA. Finally, the anticancer potential of 1-3 was tested against HeLa, A549, and NIH-3T3 cell lines. Among all, 1 with an IC50 value of 11.6 ± 1.1 μM against HeLa cells was found to be the most cytotoxic in the series. Furthermore, it has been found that the compounds induce an apoptotic mode of cell death, which is confirmed by the live cell confocal microscopy and flow cytometry techniques.

A Series of Non-Oxido VIV Complexes of Dibasic ONS Donor Ligands: Solution Stability, Chemical Transformations, Protein Interactions, and Antiproliferative Activity

A series of mononuclear non-oxido vanadium(IV) complexes, [V^IV(L^1-4)₂] (1-4), featuring tridentate bi-negative ONS chelating S-alkyl/aryl-substituted dithiocarbazate ligands H₂L^1-4, are reported. All the synthesized non-oxido V^IV compounds are characterized by elemental analysis, spectroscopy (IR, UV-vis, and EPR), ESI-MS, as well as electrochemical techniques (cyclic voltammetry). Single-crystal X-ray diffraction studies of 1-3 reveal that the mononuclear non-oxido V^IV complexes show distorted octahedral (1 and 2) or trigonal prismatic (3) arrangement around the non-oxido V^IV center. EPR and DFT data indicate the coexistence of mer and fac isomers in solution, and ESI-MS results suggest a partial oxidation of [V^IV(L^1-4)₂] to [V^V(L^1-4)₂]⁺ and [V^VO₂(L^1-4)]^-; therefore, all these three complexes are plausible active species. Complexes 1-4 interact with bovine serum albumin (BSA) with a moderate binding affinity, and docking calculations reveal non-covalent interactions with different regions of BSA, particularly with Tyr, Lys, Arg, and Thr residues. In vitro cytotoxic activity of all complexes is assayed against the HT-29 (colon cancer) and HeLa (cervical cancer) cells and compared with the NIH-3T3 (mouse embryonic fibroblast) normal cell line by MTT assay and DAPI staining. The results suggest that complexes 1-4 are cytotoxic in nature and induce cell death in the cancer cell lines by apoptosis and that a mixture of V^IV, V^V, and V^VO₂ species could be responsible for the biological activity.

Mononuclear/Binuclear [VIVO]/[VVO2] Complexes Derived from 1,3-Diaminoguanidine and Their Catalytic Application for the Oxidation of Benzoin via Oxygen Atom Transfer

Ligands H₄sal-dag (I) and H₄Brsal-dag (II) derived from 1,3-diaminoguanidine and salicylaldehyde or 5-bromosalicylaldehyde react with one or 2 mol equivalent of vanadium precursor to give two different series of vanadium complexes. Thus, complexes [V^IVO(H₂sal-dag) (H₂O)] (1) and [V^IVO(H₂Brsal-dag) (H₂O)] (2) were isolated by the reaction of an equimolar ratio of these ligands with [V^IVO(acac)₂] in MeOH. In the presence of K⁺/Cs⁺ ion and using aerially oxidized [V^IVO(acac)₂], the above reaction gave complexes [K(H₂O){V^VO₂(H₂sal-dag)}]₂ (3), [Cs(H₂O){V^VO₂(H₂sal-dag)}]₂ (4), [K(H₂O){VO₂(H₂Brsal-dag)}]₂ (5), and [Cs(H₂O){V^VO₂(H₂Brsal-dag)}]₂ (6), which could also be isolated by direct aerial oxidation of complexes 1 and 2 in MeOH in the presence of K⁺/Cs⁺ ion. Complexes [(H₂O)V^IVO(Hsal-dag)V^VO₂] (7) and [(H₂O)V^IVO(HBrsal-dag)V^VO₂] (8) were isolated upon increasing the ligand-to-vanadium precursor molar ratio to 1:2 under an air atmosphere. When I and II were reacted with aerially oxidized [V^IVO(acac)₂] in a 1:2 molar ratio in MeOH in the presence of K⁺/Cs⁺ ion, they formed [K(H₂O)₅{(V^VO₂)₂(Hsal-dag)}]₂ (9), [Cs(H₂O)₂{(V^VO₂)₂(Hsal-dag)}]₂ (10), [K₂(H₂O)₄{(V^VO₂)₂(Brsal-dag)}]₂ (11), and [Cs₂(H₂O)₄{(V^VO₂)₂(Brsal-dag)}]₂ (12). The structures of complexes 3, 4, 5, and 9 determined by single-crystal X-ray diffraction study confirm the mono-, bi-, tri-, and tetra-anionic behaviors of the ligands. All complexes were found to be an effective catalyst for the oxidation of benzoin to benzil via oxygen atom transfer (OAT) between DMSO and benzoin. Under aerobic condition, this oxidation also proceeds effectively in the absence of DMSO. Electron paramagnetic resonance and ⁵¹V NMR studies demonstrated the active role of a stable V(IV) intermediate during OAT between DMSO and benzoin.

Ruthenium(II)-Dithiocarbazates as Anticancer Agents: Synthesis, Solution Behavior, and Mitochondria-Targeted Apoptotic Cell Death

The reaction of the Ru(PPh₃ )₃ Cl₂ with HL^1-3 -OH (-OH stands for the oxime hydroxyl group; HL¹ -OH=diacetylmonoxime-S-benzyldithiocarbazonate; HL² -OH=diacetylmonoxime-S-(4-methyl)benzyldithiocarbazonate; and HL³ -OH=diacetylmonoxime-S-(4-chloro)benzyl-dithiocarbazonate) gives three new ruthenium complexes [Ru^II (L^1-3 -H)(PPh₃ )₂ Cl] (1-3) (-H stands for imine hydrogen) coordinated with dithiocarbazate imine as the final products. All ruthenium(II) complexes (1-3) have been characterized by elemental (CHNS) analyses, IR, UV-vis, NMR (¹ H, ¹³ C, and ³¹ P) spectroscopy, HR-ESI-MS spectrometry and also, the structure of 1-2 was further confirmed by single crystal X-ray crystallography. The solution/aqueous stability, hydrophobicity, DNA interactions, and cell viability studies of 1-3 against HeLa, HT-29, and NIH-3T3 cell lines were performed. Cell viability results suggested 3 being the most cytotoxic of the series with IC₅₀ 6.9±0.2 μM against HeLa cells. Further, an apoptotic mechanism of cell death was confirmed by cell cycle analysis and Annexin V-FITC/PI double staining techniques. In this regard, the live cell confocal microscopy results revealed that compounds primarily target the mitochondria against HeLa, and HT-29 cell lines. Moreover, these ruthenium complexes elevate the ROS level by inducing mitochondria targeting apoptotic cell death.

Mitochondria-Targeted Luminescent Organotin(IV) Complexes: Synthesis, Photophysical Characterization, and Live Cell Imaging

Five fluorescent ONO donor-based organotin(IV) complexes, [Sn^IV(L^1-5)Ph₂] (1-5), were synthesized by the one-pot reaction method and fully characterized spectroscopically including the single-crystal X-ray diffraction studies of 2-4. Detailed photophysical characterization of all compounds was performed. All the compounds exhibited high luminescent properties with a quantum yield of 17-53%. Additionally, the results of cellular permeability analysis suggest that they are lipophilic and easily absorbed by cells. Confocal microscopy was used to examine the live cell imaging capability of 1-5, and the results show that the compounds are mostly internalized in mitochondria and exhibit negligible cytotoxicity at imaging concentration. Also, 1-5 exhibited high photostability as compared to the commercial dye and can be used in long-term real-time tracking of cell organelles. Also, it is found that the probes (1-5) are highly tolerable during the changes in mitochondrial morphology. Thus, this kind of low-toxic organotin-based fluorescent probe can assist in imaging of mitochondria within living cells and tracking changes in their morphology.

Exploring Anticancer Activities and Structure-Activity Relationships of Binuclear Oxidovanadium(IV) Complexes

Dimeric mixed-ligand oxidovanadium complexes [V₂O₂(1,3-pdta)(bpy)₂]·9H₂O (1) and [V₂O₂(1,3-pdta)(phen)₂]·6H₂O (2) feature a symmetric binuclear structure bridged by 1,3-pdta, which is different from our previous reported asymmetric binuclear complex [V₂O₂(edta)(phen)₂]·11H₂O (3).In this study, a wide range of analytical techniques were carried out to fully characterize the complexes 1 and 2 and further investigate their structural stabilities. Density functional theory calculations of 1 and 2 also suggest that they might have good reactivity with biomolecules as anticancer agents. To assess and screen the antitumor activities of compounds 1-3 together with their four corresponding monomeric complexes [VO(ida)(phen)], [VO(ida)(bpy)], [VO(OH)(phen)₂]Cl, and [VO(Hedta)]^-, we have performed in vitro experiments with hepatocellular carcinoma HepG2 and SMMC-7721 cell lines by MTT analyses. Complex 2 was found to have the highest inhibitory potency against the growth of HepG2 and SMMC-7721 cells (IC₅₀ = 2.07 ± 0.72 μM for HepG2; 13.00 ± 3.06 μM for SMMC-7721) compared to other compounds. The structure-activity relationship studies showed that the antitumor effect of compound 2 is higher than that of other compounds. After studying the monomeric compounds of 1-3, their effects were also ranked. Moreover, complex 2 displayed stronger binding affinity toward calf thymus DNA (K_b = 5.71 × 10⁴ M^-1) and cleavage activities than the other complexes (K_b = 1.34 × 10⁴ M^-1 for 1 and 5.22 × 10⁴ M^-1 for 3, respectively). We further extended the cellular mechanisms of drug action and found that 2 could block DNA synthesis and cell division of HepG2 and 7721 cells and further induce apoptosis by flow cytometry assays. In short, these results indicate that binuclear oxidovanadium compounds could have potential as simple, effective, and safe antitumor agents.

Water-Soluble Dioxidovanadium(V) Complexes of Aroylhydrazones: DNA/BSA Interactions, Hydrophobicity, and Cell-Selective Anticancer Potential

Five new anionic aqueous dioxidovanadium(V) complexes, [{VO₂L^1,2}A(H₂O)_n]_α (1-5), with the aroylhydrazone ligands pyridine-4-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)hydrazide (H₂L¹) and furan-2-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)hydrazide (H₂L²) incorporating different alkali metals (A = Na⁺, K⁺, Cs⁺) as countercation were synthesized and characterized by various physicochemical techniques. The solution-phase stabilities of 1-5 were determined by time-dependent NMR and UV-vis, and also the octanol/water partition coefficients were obtained by spectroscopic techniques. X-ray crystallography of 2-4 confirmed the presence of vanadium(V) centers coordinated by two cis-oxido-O atoms and the O, N, and O atoms of a dianionic tridentate ligand. To evaluate the biological behavior, all complexes were screened for their DNA/protein binding propensity through spectroscopic experiments. Finally, a cytotoxicity study of 1-5 was performed against colon (HT-29), breast (MCF-7), and cervical (HeLa) cancer cell lines and a noncancerous NIH-3T3 cell line. The cytotoxicity was cell-selective, being more active against HT-29 than against other cells. In addition, the role of hydrophobicity in the cytotoxicity was explained in that an optimal hydrophobicity is essential for high cytotoxicity. Moreover, the results of wound-healing assays indicated antimigration in case of HT-29 cells. Remarkably, 1 with an IC₅₀ value of 5.42 ± 0.15 μM showed greater activity in comparison to cisplatin against the HT-29 cell line.

Protein binding and cytotoxic activities of monomeric and dimeric oxido-vanadium(V) salan complexes: Exploring the solution behavior of monoalkoxido-bound oxido-vanadium(V) complex

Three ONNO donor tetradentate diamino bis(phenolato) "salan" ligands, N, N'-dimethyl-N, N'-bis-(5-chloro-2-hydroxy-3-methyl-benzyl)-1,2-diaminoethane (H₂L¹), N, N'-dimethyl-N, N'-bis-(5-chloro-2-hydroxy-3-isopropyl-6-methyl-benzyl)-1,2-diamino-ethane (H₂L²) and N, N'-bis-(5-chloro-2-hydroxy-3-isopropyl-6-methyl-benzyl)-1,2-diaminocyclohexane (H₂L³) have been synthesized by following Mannich condensation reaction. Reaction of these ligands with their corresponding vanadium metal precursors gave one oxidomethoxidovanadium(V) [V^VOL¹(OCH₃)] (1) and two monooxido-bridged divanadium (V, V) complexes [V^VOL^2-3]₂(μ-O) (2-3). The complexes were characterized by IR, UV-vis, NMR and ESI mass spectrometry. Also, the structure of all the complexes (1-3) was confirmed by the Single-Crystal X-ray diffraction analysis, which revealed a distorted octahedral geometry around the metal centres. The solution behavior of the [V^VOL¹(OCH₃)] (1) reveals the formation of two different types of V(V) species in solution, the structurally characterized compound 1 and its corresponding monooxido-bridged divanadium (V, V) complex [V^VOL¹]₂(μ-O), which was further studied by IR, and NMR spectroscopy. The electrochemical behavior of all the complexes was evaluated through cyclic voltammetry. Interaction of the salan-V(V) complexes with human serum albumin (HSA) and bovine serum albumin (BSA) were analysed through fluorescence quenching, UV-vis absorption titration, synchronous fluorescence, circular dichroism studies, and förster resonance energy transfer (FRET). Finally, the in vitro cytotoxicity of the complexes was investigated against MCF-7 and HT-29 and NIH-3T3 cell lines. Cytotoxicity value of complexes in both MCF-7 and HT-29 follows the same trend that is 3 > 1 > 2 which is in line with protein binding affinity of the complexes.

Study of DNA Interaction and Cytotoxicity Activity of Oxidovanadium(V) Complexes with ONO Donor Schiff Base Ligands

Two new oxidovanadium(V) complexes, (HNEt3)[VVO2L] (1) and [(VVOL)2μ-O] (2), have been synthesized using a tridentate Schiff base ligand H2L [where H2L = 4-((E)-(2-hydroxy-5-nitrophenylimino)methyl)benzene-1,3-diol] and VO(acac)2 as starting metal precursor. The ligand and corresponding metal complexes are characterized by physicochemical (elemental analysis), spectroscopic (FT-IR, UV–Vis, and NMR), and spectrometric (ESI–MS) methods. X-ray crystallographic analysis indicates the anion in salt 1 features a distorted square-pyramidal geometry for the vanadium(V) center defined by imine-N, two phenoxide-O, and two oxido-O atoms. The interaction of the compounds with CT–DNA was studied through UV–Vis absorption titration and circular dichroism methods. The results indicated that complexes showed enhanced binding affinity towards DNA compared to the ligand molecule. Finally, the in vitro cytotoxicity studies of H2L, 1, and 2 were evaluated against colon cancer (HT-29) and mouse embryonic fibroblast (NIH-3T3) cell lines by MTT assay. The results demonstrated that the compounds manifested a cytotoxic potential comparable with clinically referred drugs and caused cell death by apoptosis.

Probing CO Generation through Metal-Assisted Alcohol Dehydrogenation in Metal-2-(arylazo)phenol Complexes Using Isotopic Labeling (Metal = Ru, Ir): Synthesis, Characterization, and Cytotoxicity Studies

The reaction of 2-{2-(benzo[1,3]dioxol-5-yl)- diazo}-4-methylphenol (HL) with [Ru(PPh₃)₃Cl₂] in ethanol resulted in the carbonylated ruthenium complex [RuL(PPh₃)₂(CO)] (1), wherein metal-assisted decarbonylation via in situ ethanol dehydrogenation is observed. When the reaction was performed in acetonitrile, however, the complex [RuL(PPh₃)₂(CH₃CN)] (2) was obtained as the main product, probably by trapping of a common intermediate through coordination of CH₃CN to the Ru(II) center. The analogous reaction of HL with [Ir(PPh₃)₃Cl] in ethanol did not result in ethanol decarbonylation and instead gave the organoiridium hydride complex [IrL(PPh₃)₂(H)] (3). Unambiguous evidence for the generation of CO via ruthenium-assisted ethanol oxidation is provided by the synthesis of the ¹³C-labeled complex, [Ru(PPh₃)₂L(¹³CO)] (1A) using isotopically labeled ethanol, CH₃¹³CH₂OH. To summarize all the evidence, a ruthenium-assisted mechanistic pathway for the decarbonylation and generation of alkane via alcohol dehydrogenation is proposed. In addition, the in vitro antiproliferative activity of complexes 1-3 was tested against human cervical (HeLa) and human colorectal adenocarcinoma (HT-29) cell lines. Complexes 1-3 showed impressive cytotoxicity against both HeLa (half-maximal inhibitory concentration (IC₅₀) value of 3.84-4.22 μM) and HT-29 cancer cells (IC₅₀ values between 3.3 and 4.5 μM). Moreover, the complexes were comparatively less toxic to noncancerous NIH-3T3 cells.

New VIV, VIVO, VVO, and VVO2 Systems: Exploring their Interconversion in Solution, Protein Interactions, and Cytotoxicity

The synthesis and characterization of one oxidoethoxidovanadium(V) [V^VO(L¹)(OEt)] (1) and two nonoxidovanadium(IV) complexes, [V^IV(L^2-3)₂] (2 and 3), with aroylhydrazone ligands incorporating naphthalene moieties, are reported. The synthesized oxido and nonoxido vanadium complexes are characterized by various physicochemical techniques, and their molecular structures are solved by single crystal X-ray diffraction (SC-XRD). This revealed that in 1 the geometry around the vanadium atom corresponds to a distorted square pyramid, with a O₄N coordination sphere, whereas that of the two nonoxido V^IV complexes 2 and 3 corresponds to a distorted trigonal prismatic arrangement with a O₄N₂ coordination sphere around each "bare" vanadium center. In aqueous solution, the V^VO moiety of 1 undergoes a change to V^VO₂ species_, yielding [V^VO₂(L¹)]^- (1'), while the nonoxido V^IV-compounds 2 and 3 are partly converted into their corresponding V^IVO complexes, [V^IVO(L^2-3)(H₂O)] (2' and 3'). Interaction of these V^VO₂, V^IVO, and V^IV systems with two model proteins, ubiquitin (Ub) and lysozyme (Lyz), is investigated through docking approaches, which suggest the potential binding sites: the interaction is covalent for species 2' and 3', with the binding to Glu16, Glu18, and Asp21 for Ub, and His15 for Lyz, and it is noncovalent for species 1', 2, and 3, with the surface residues of the proteins. The ligand precursors and complexes are also evaluated for their in vitro antiproliferative activity against ovarian (A2780) and prostate (PC3) human cancer cells and in normal fibroblasts (V79) to check the selectivity of the compounds for cancer cells.

Synthesis, structure and characterization of new dithiocarbazate-based mixed ligand oxidovanadium(iv) complexes: DNA/HSA interaction, cytotoxic activity and DFT studies

The synthesis, structure and characterization of mixed ligand oxidovanadium(iv) complexes [V^IVOL^1–2(L^N–N)] (1–3) are reported. With a view to evaluating their biological activity, their DNA/HSA interaction and cytotoxicity activity have been explored.

Unusual chemistry of Cu(ii) salan complexes: synthesis, characterization and superoxide dismutase activity

Cu(ii)-salan complexes: structural and spectral characterization, solvent assisted ring cleavage and correlation of superoxide dismutase activity with cyclic voltammetry data and steric effects.

Polynuclear zinc(II) complexes of thiosemicarbazone: Synthesis, X-ray structure and biological evaluation

Two new dimeric Zn(II) ([{ZnL¹(DMSO₂)}₂]·DMSO (1), [{ZnL²Cl}₂] (2)) and a novel tetrameric Zn(II) complex ([(Zn₂L³)₂(μ-OAc)₂(μ₃-O)₂] (3)), where H₂L¹ = 4-(p-methoxyphenyl) thiosemicarbazone of o-hydroxynapthaldehyde, HL² = 4-(p-methoxyphenyl)thiosemicarbazone of benzoyl pyridine and H₂L³ = 4-(p-chlorophenyl)thiosemicarbazone of o-vanillin are reported. Ligands and their complexes were characterized by spectroscopic and single crystal X-ray diffraction techniques. In addition, the complexes exhibited good binding affinity towards HSA (10¹² M^-1), which is supported by their ability to quench the tryptophan fluorescence emission spectra of HSA. The complexes were also screened for their DNA binding propensity through UV-vis absorption titration, circular dichroism and fluorescence spectral studies. Results show that they effectively interact with CT-DNA through an intercalative mode of binding, with binding constants ranging from 10³ to 10⁴ M^-1. Among the three complexes 1 has the highest binding affinity towards CT-DNA. Further, the phosphatase activity was evaluated using bis(2,4-dinitrophenyl)phosphate (BDNPP) as substrate, however, the complexes did not yield any measurable catalytic activity. Nevertheless the complexes showed significant cytotoxic potential against HeLa and HT-29 cancer cell lines that was assessed through MTT assay and DAPI staining. Remarkably, complex 1 showed better activity than cisplatin against HT-29 cell line.

Probing the chirality of oxidovanadium(v) centers in complexes with tridentate sugar Schiff-base ligands: solid-state and solution behavior

Configurations of oxidovanadium centers in diastereomeric complexes with chiral sugar ligands are assigned and in the solid state triggered by the coordination number at the vanadium center through the steric requirements of the chelate ligand.

Synthesis, crystal structure, DFT calculations, protein interaction, anticancer potential and bromoperoxidase mimicking activity of oxidoalkoxidovanadium(v) complexes

Intriguing structure–activity relationships (SARs) indicating an apparent dependence of anticancer and haloperoxidase activities on the carbon chain length of the alkoxo group.

In vitrocytotoxicity and catalytic evaluation of dioxidovanadium(v) complexes in an azohydrazone ligand environment

Synthesis, characterization,in vitrocytotoxicity and catalytic potential of the dioxidovanadium(v) complexes of azohydrazones.

Synthesis, structure and biological evaluation of mixed ligand oxidovanadium(iv) complexes incorporating 2-(arylazo)phenolates

Synthesis and characterization of mixed ligand oxidovanadium(iv) complexes [V^IVO(L^1–4)(L^NN)] incorporating arylazo ligands: evaluation of DNA/BSA interaction and cytotoxicity activity.